Daniel O'Day, Gilead CEO (Paras Griffin/Getty Images for ESSENCE)
February 26, 2024 06:51 AM EST
Deals
Pharma

Gilead bid against it­self in $4.3B deal for CymaBay, fil­ing shows

Kyle LaHucik

Senior Reporter

Gilead Sci­ences was the sole bid­der for liv­er dis­ease biotech CymaBay Ther­a­peu­tics and ul­ti­mate­ly hiked up its ini­tial pro­pos­al by $9.50 per share, ac­cord­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times